Conjoint Associate Professor
Dr Dorit Samocha-Bonet
Academic Record
|
2001 - 2006 |
PhD, Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Israel. |
|
1993 - 1996 |
MSc, Clinical Biochemistry, Sackler School of Medicine, Tel-Aviv University, Israel. With Honours. |
|
1989 - 1992 |
BSc, Nutritional Sciences, Hebrew University, Faculty of Agricultural, Food and Environmental Quality Sciences, Israel. Cum Laude. |
Other Qualifications
1993 Dietitian (recognition by the Israeli Ministry of Health, Department of Medical Professions)
Medicine & Health
School of Clinical Medicine
Samocha-Bonet is Group leader, Clinical Insulin Resistance at the Healthy Ageing Theme at the Garvan Institute of Medical Research, and a Conjoint Senior Lecturer, School of Medical Sciences UNSW. Samocha-Bonet completed a BSc degree (Cum Laude) in Nutritional Sciences at the Hebrew University, Israel and joined the Nutrition & Dietetics Department at Tel Aviv Medical Centre as a clinical dietician where she worked for a decade (1993-2003). She completed MSc degree (with Honours) in Clinical Biochemistry (1996) and PhD in Physiology & Pharmacology (2006) at Tel Aviv University, Israel prior to relocating to Sydney. She joined the Garvan Institute of Medical Research in 2007 as a postdoctoral fellow. In 2013 she established the Clinical Insulin Resistance Group with a focus on exploring the metabolic factors underlying insulin resistance and insulin sensitivity in obesity and on developing approaches to promoting insulin sensitivity in obesity. She has been the Australian Diabetes Society (ADS) Skip Martin Early Career Fellow in 2011, and the recipient of the top ranked project grant from the Diabetes Australia Research Program in 2016.
Phone
+61292958309
E-mail
Location
Garvan Institute of Medical Research
384 Victoria Street
Darlinghurst 2010
- Publications
- Media
- Grants
- Awards
- Research Activities
- Engagement
- Teaching and Supervision
Research at the Clinical Insulin Resistance Group at the Garvan is focused on uncovering the molecular pathways involved in the transition from health to insulin resistance and metabolic disease related to overweight and obesity in humans. In our clinical studies, we use gold-standard protocols to deeply phenotype individuals at risk of type 2 diabetes. Using gold-standard tools to characterise whole-body glucose regulation, abdominal fat distribution and liver fat, we find a wide range of phenotypic variation in obesity and prediabetes.
Current projects:
- A randomised clinical trial (https://clinicaltrials.gov/NCT03558867) to test the efficacy of an algorithm-based (personalised) diet in combination with metformin on glycaemia in individuals with prediabetes and type 2 diabetes (in collaboration with Prof Elinav and Prof Segal, The Weizmann Institute of Science).
- Reverse engineering insulin secretion in health and disease (in collaboration with leading obesity clinicians in hospitals across Sydney) - PhD project available in clinical study settings